BLFS
BioLife Solutions, Inc.24.61
-0.04-0.16%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.18BP/E (TTM)
-Basic EPS (TTM)
-0.38Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
Annual meeting results affirm governance
BioLife Solutions held its 2025 annual meeting on August 20, where stockholders re-elected directors Roderick de Greef, Catherine Coste, Amy DuRoss, Rachel Ellingson, Joydeep Goswami, Tony Hunt, and Timothy Moore, despite notable withheld votes for Ellingson and Goswami. The advisory vote approved executive compensation, and the Audit Committee’s appointment of Grant Thornton LLP as auditors for the fiscal year ending December 31, 2025, was ratified with near-unanimous support. Votes tallied from 43 million shares present. Continuity in governance persists, yet scrutiny on select board members lingers.
8-K
Q2 revenue up 28%
BioLife Solutions reported Q2 2025 cell processing revenue of $23.0 million, surging 28% year-over-year amid strong biopreservation media demand from 16 approved CGT therapies and over 250 clinical trials. A $15.5 million non-cash IPR&D expense from the April 4 acquisition of PanTHERA's remaining 90% stake drove GAAP net loss to $15.8 million, yet adjusted EBITDA hit $6.1 million or 24% of revenue. The company raised full-year revenue guidance to $100.0-$103.0 million, signaling robust growth. Momentum builds.
10-Q
Q2 FY2025 results
BioLife Solutions posted solid revenue growth in Q2 FY2025 ended June 30, 2025, with total revenue up 29% y/y to $25.4M, driven by 28% y/y gains in cell processing to $22.9M amid recovering customer demand, while evo and Thaw products surged 366% y/y to $0.8M from new wins. Gross margins held steady at 38% despite a less favorable mix, but operating loss widened to $16.6M from a $15.5M IPR&D charge tied to the April 2025 PanTHERA acquisition for $16.8M (cash and stock), which bolstered cryopreservation tech without immediate synergies. Net loss hit $15.8M or $(0.33) diluted EPS on 47.8M shares, versus $(0.12) last year, with the gap mainly from that non-cash hit and higher stock-based comp. Cash and equivalents fell to $31.9M from $95.4M, yet liquidity stays robust at $100.2M including securities, with $10.1M debt maturing June 2026 at 7.0%; free cash flow not disclosed in the 10-Q. PanTHERA closed in April 2025 for ~$16.8M (cash/stock per Note 2), recognizing no goodwill as an asset acquisition. Still, regulatory hurdles in CGT approvals could slow adoption.
IPO
Employees
Sector
Industry
AZTA
Azenta, Inc.
34.31-0.77
BIO
Bio-Rad Laboratories, Inc.
302.02-5.90
BLGO
BioLargo, Inc.
0.18+0.00
CCEL
Cryo-Cell International, Inc.
3.80+0.06
CYRX
CryoPort, Inc.
9.24+0.00
HBIO
Harvard Bioscience, Inc.
0.70-0.00
PLSE
Pulse Biosciences, Inc
14.23+0.10
RSCF
Reflect Scientific, Inc.
0.05+0.00
SOAGY
Sartorius AG
56.43-0.16
TMO
Thermo Fisher Scientific Inc
570.16-5.75